Lisinopril: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension and Congestive Heart Failure

Drugs

Volumn 35, Issue 6, 1988, Pages 646-669

  Lancaster, Simon G ^a   Todd, Peter A ^a  

^a Manchester International Law Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOPROLOL; NIFEDIPINE;

AGE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; ETHNIC OR RACIAL ASPECTS; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; ENALAPRIL; HEART FAILURE, CONGESTIVE; HUMAN; HYPERTENSION; LISINOPRIL;

EID: 0023764202     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198835060-00003     Document Type: Article

References (75)

1. Clinical pharmacology of enalapril
2. Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man
3. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril
4. The effect of enalapril on baroreceptor-mediated reflex function in normotensive subjects
5. Disparate cardiac effects of afterload reduction in hypertension
6. Lisinopril steady state kinetics in healthy subjects. Abstract
7. Pharmacokinetics of lisinopril in healthy volunteers. Abstract no. 130
8. Three new long-acting converting enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I
9. Enalapril maleate and a lysine analogue (MK 521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system
10. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension
11. Effect of a new angiotensin-converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects
12. Purification of angiotensin-converting enzyme from rabbit lung and human plasma by affinity chromatography
13. Inhibition of rabbit lung angiotensin-converting enzyme by N-[(s)-l-carboxy-3-phenylpropyl]L-alanyl-L-proline and N-[(s)-l-carboxy-3-phenylpropyl]L-lysyl-L-proline
14. Once-daily lisinopril in hypertensive patients: effect on blood pressure and the renin-angiotensin system
15. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study
16. Effect of age on lisinopril pharmacokinetics. Abstract no. B5
17. Lisinopril in hypertensive patients with renal dysfunction. Abstract no. 8
18. Lisinopril: dose-peak effect relationship in essential hypertention. British Journal of Clinical Pharmacology, in press, 1988 CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
19. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors
20. Acute haemodynamic and hormonal effects of lisinopril (MK 521) in congestive heart failure
21. A comparison of hypotensive responses after oral and intravenous administration of enalapril and lisinopril in chronic heart failure
22. Lisinopril in hypertension associated with renal impairment
23. Long term monotherapy with lisinopril in renovascular hypertension
24. Lisinopril in hypertensive patients with impaired renal function. Abstract no. PPH4
25. Pharmacokinetics of lisinopril (MK 521) in healthy young and elderly subjects and in elderly patients with cardiac failure
26. Effects of MK 521 (lisinopril) on the renal plasma flow and renin-angiotensin-aldosterone system in patients with essential hypertension
27. Abnormal regional blood flow response to exercise in patients with heart failure corrected by lisinopril. Abstract no. 557
28. Lisinopril dose response in mild to moderate hypertension. Abstract no. C48
29. Efficacy of lisinopril in elderly patients with congestive heart failure. Abstract no. 131
30. The clinical pharmacology of lisinopril
31. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy
32. Radioimmunoassay for angiotensin-converting enzyme inhibitors. Abstract
33. Enalapril (MK421) and its lysine analogue (MK 521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man
34. Enalapril and lisinopril in renovascular hypertension — antihypertensive and hormonal effects of two new angiotensin-converting enzyme (ACE) inhibitors: a preliminary report
35. Antihypertensive and hormonal effects of lisinopril, a new angiotensin-converting enzyme (ACE) inhibitor in patients with renovascular hypertension
36. Acute and chronic dose pharmacokinetics of lisonopril, effects of renal impairment
37. A 52-week comparison of lisinopril, hydrochlorothiazide and their combination in hypertension
38. The effect of chronic lisinopril therapy on blood pressure and intracellular calcium in patients with hypertension
39. A clinical pharmacological study of nifedipine and lisinopril alone and in combination
40. Lisinopril in the treatment of chronic cardiac failure: a controlled trial. Abstract no. 2035
41. Lisinopril/HCTZ in essential hypertension. Abstract no. P III I-2
42. Pharmacodynamics of converting enzyme inhibition: the cardiovascular endocrine and autonomic effects of MK421 (enalapril) and MK521
43. Effect of food on the bioavailability of lisinopril, a non-sulfhydryl angiotensin-converting enzyme inhibitor
44. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension
45. An acute pharmacokinetic study of the potential interaction of lisinopril and digoxin in normal volunteers
46. Dose response study of lisinopril efficacy in hypertension. Abstract
47. Lack of angiotensin I accumulation after converting enzyme blockade by enalapril or lisinopril in man
48. Controlled multicentre study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension
49. A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure
50. Lisinopril in essential hypertension: a six month comparative study with nifedipine
51. Initial evaluation of the non-sulfhydryl-containing converting enzyme inhibitor MK521 in hypertensive humans
52. The safety and tolerability of lisinopril in clinical trials
53. Biological activity of two new angiotensin-converting enzyme inhibitors in healthy volunteers. Abstract no. A-17
54. Evaluation of the antihypertensive effect of lisinopril compared to atenolol in Black, Mixed and Indian patients with mild-to-moderate essential hypertension
55. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man
56. Indomethacin does not blunt the antihypertensive effect of lisinopril. Abstract no. p III B-10
57. Persistent hemodynamic effects of lisinopril after chronic therapy in congestive heart failure. Abstract
58. Lisinopril versus atenolol alone and with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
59. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK 421) in normal volunteers
60. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure
61. Enalapril maleate and lysine analogue (MK521): disposition in man
62. Treatment of severe heart failure with lisinopril: acute and chronic hemodynamic echocardiographic, and clinical responses. Abstract no. 1624
63. Lisinopril in hypertensive patients with and without renal failure
64. Lisinopril dose and duration of effect in patients with congestive heart failure. Abstract no. 132
65. Comparative effects of enalapril, lisinopril and nitrendipine on plasma lipid concentrations in hypertensive subjects
66. Radioimmunoassay for the quantitation of lisinopril and enalaprilat
67. Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension